Gastric (Stomach) CancerNCT07213115
Epidemiology and Treatment of Gastric Cancer
An observational study of Gastric (Stomach) Cancer and Sex Difference, run by Medizinische Hochschule Brandenburg Theodor Fontane.
Trial summary
According to recent statistics, the incidence and mortality from gastric cancer are both worldwide in fifth place in terms of ranking. Gastric cancer is more common in males than in females. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Gastric (Stomach) Cancer, Sex Difference
- What is being tested?
- Gastrectomy+ chemotherapy
- Type of treatment
- Surgery or procedure
- How many people
- 8,582 participants
- Where
- No sites listed yet
- Study dates
- 1 Jan 2000to 31 Dec 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The analysis focused on patients diagnosed with gastric adenocarcinomas (ICD-10-GM: C16.0 -C16.9) between 2000 and 2020 and residing in the Federal State Brandenburg. The data status was 31. December 2020. In the period between 2000 and 2020, a total of 8 582 patients residing in the state Brandenburg with newly diagnosed gastric adenocarcinoma were documented in the Cancer Registry and provided for the analysis in this study.
Who may be able to join
- gastric adenocarcinomas (ICD-10-GM: C16.0 -C16.9)
Who cannot join
- missing age or sex
About this study
Official title: Epidemiology and Treatment of Gastric Cancer in the Federal State of Brandenburg From 2000 to 2020. An Analysis Using Data From the Clinical Cancer Registry for Brandenburg and Berlin.
According to recent statistics, the incidence and mortality from gastric cancer are both worldwide in fifth place in terms of ranking. Gastric cancer is more common in males than in females. This difference in the incidence between males and females is likely due to the difference in exposure to some risk factors like Helicobacter pylori infection, family history of gastric cancer, dietary habits, smoking and alcohol. However these factors do not completely explain the different characteristics of gastric cancer between the sexes. Some studies have concluded that exposure to estrogen could reduce the risk of gastric cancer.
There is a lack of current population based and real world data on sex and age differences in gastric cancer care. Analyses of sex differences are primarily originate from Asia or focusing on older cohorts. In the Netherlands, Kalff et al. conducted a study with patients with gastric adenocarcinoma (n=2 072) registered in the Dutch Upper GI Cancer Audit between 2011 and 2016. In this study, patients without metastatic gastric cancer and with an elective surgery were included.
To close this sex and age data gap for patients including those with UICC IV stage and without surgery, the aim of our study was to analyze the sex and age differences in clinicopathological features and staging in gastric adenocarcinoma with cancer registry data from the Federal State of Brandenburg from 2000 to 2020.
- Conditions
- Gastric (Stomach) Cancer, Sex Difference
- Being tested
- Gastrectomy+ chemotherapy
- Keywords
- Gastric Cancer, sex difference, registry data, epidemiology, treatment
- Medical subject headings
- Stomach Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gastrectomy+ chemotherapyProcedure or surgery
| Study group | Role | What they receive |
|---|---|---|
| sex | Not described Receives: Procedure: Gastrectomy+ chemotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall survival
Survival time after date of cancer diagnosis
Measured: 5 year, 10 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2025
- Study start1 Jan 2000
- Primary completion31 Dec 2020
- Study completion31 Dec 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gastric (Stomach) CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 8,582 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medizinische Hochschule Brandenburg Theodor Fontane
- Sponsor type
- University, hospital or other
- Collaborators
- Margarete-Ammon-Stiftung
- Responsible party
- Principal investigator, Ulrike Weber, Medizinische Hochschule Brandenburg Theodor Fontane
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07213115
- Sponsor's protocol ID
- EpiGaCa
- Status last verified
- Oct 2025
- First submitted
- 1 Oct 2025
- Last updated
- 8 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Epidemiology and Treatment of Gastric Cancer in the Federal State of Brandenburg From 2000 to 2020. An Analysis Using Data From the Clinical Cancer Registry for Brandenburg and Berlin.
- ClinicalTrials.gov ID
- NCT07213115
- Acronym / sponsor ID
- EpiGaCa
- Conditions
- Gastric (Stomach) Cancer, Sex Difference
- Keywords
- Gastric Cancer, sex difference, registry data, epidemiology, treatment
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 8,582 participants (actual)
- Lead sponsor
- Medizinische Hochschule Brandenburg Theodor FontaneUniversity, hospital or other
- Collaborators
- Margarete-Ammon-Stiftung
- Study start
- 1 Jan 2000 (actual)
- Primary completion
- 31 Dec 2020 (actual)
- Study completion
- 31 Dec 2020 (actual)
- First posted
- 8 Oct 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
According to recent statistics, the incidence and mortality from gastric cancer are both worldwide in fifth place in terms of ranking. Gastric cancer is more common in males than in females. This difference in the incidence between males and females is likely due to the difference in exposure to some risk factors like Helicobacter pylori infection, family history of gastric cancer, dietary habits, smoking and alcohol. However these factors do not completely explain the different characteristics of gastric cancer between the sexes. Some studies have concluded that exposure to estrogen could reduce the risk of gastric cancer.
There is a lack of current population based and real world data on sex and age differences in gastric cancer care. Analyses of sex differences are primarily originate from Asia or focusing on older cohorts. In the Netherlands, Kalff et al. conducted a study with patients with gastric adenocarcinoma (n=2 072) registered in the Dutch Upper GI Cancer Audit between 2011 and 2016. In this study, patients without metastatic gastric cancer and with an elective surgery were included.
To close this sex and age data gap for patients including those with UICC IV stage and without surgery, the aim of our study was to analyze the sex and age differences in clinicopathological features and staging in gastric adenocarcinoma with cancer registry data from the Federal State of Brandenburg from 2000 to 2020.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| sex | – | Procedure: Gastrectomy+ chemotherapy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The analysis focused on patients diagnosed with gastric adenocarcinomas (ICD-10-GM: C16.0 -C16.9) between 2000 and 2020 and residing in the Federal State Brandenburg. The data status was 31. December 2020. In the period between 2000 and 2020, a total of 8 582 patients residing in the state Brandenburg with newly diagnosed gastric adenocarcinoma were documented in the Cancer Registry and provided for the analysis in this study.
Key inclusion criteria (1 listed)
- gastric adenocarcinomas (ICD-10-GM: C16.0 -C16.9)
Key exclusion criteria (1 listed)
- missing age or sex
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gastrectomy+ chemotherapy | Procedure or surgery | sex |
Primary outcome
Overall survival
Time frame: 5 year, 10 year
Survival time after date of cancer diagnosis
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Oct 2025.
- Individual participant dataSharing planned: No
Related trials for Gastric (Stomach) Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
Not yet recruitingPhase 1
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
Gastric Cancer (GC)
RecruitingPhase 3
A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC.
Gastric, Esophagogastric Junction
Active, not recruitingEarly Phase 1
Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma
B-ALL, DLBCL
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Gastric (Stomach) Cancer and Sex Difference, run by Medizinische Hochschule Brandenburg Theodor Fontane.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall survival (time frame: 5 year, 10 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Oct 2025.